The discrepancy of preclinical observations and limited clinical success of CXCR4 antagonists as cancer therapy strongly advocates the involvement of some other aspects of CXCR4 biology beyond its classical CXCR4-CXCL12 signaling axis. Here, CXCL12 is linked to cancer.